Caricamento in corso... Attendere.
Profilo società
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows:
- revenues from collaboration and licensing agreements (84.2%);
- government financing for research expenditure (15.8%).
Fonte:
Cofisem
-
Ultimo aggiornamento:
29 Mar 2025
Dirigenti principali
| Chairman of the Management Board | Jonathan Dickinson | ||||
| Member of the Management Board | Yannis Morel | ||||
| Chief Operating Officer | Yannis Morel | ||||
| Member of the Management Board | Sonia Quaratino | ||||
| Member of the Management Board | Arvind Sood | ||||
| Chief Financial Officer | Frédéric Lombard | ||||
| Director of Development | Nicola Beltraminelli | ||||
| Chief Human Resources Officer | Odile Laurent | ||||
| General Counsel | Claire Saint Blanquat | ||||
| Chief Communication Officer | Henry Wheeler | ||||
| Head of Investor Relations | Henry Wheeler | ||||
| Fonte: Cofisem - Ultimo aggiornamento: 29 Mar 2025 | |||||
Dati principali
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 12.622 | 51.901 | 49.580 | 12.112 | 56.155 |
| Income from ordinary activities | 20.121 | 51.901 | 49.580 | 12.112 | 56.155 |
| Operating income | -51.575 | -12.669 | -57.425 | -47.825 | 1.079 |
| Cost of financial indebtedness net | 640 | 288 | 312 | 341 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | 0 | -131 | -7.329 | -63.155 | |
| Net income | -49.471 | -7.570 | -58.103 | -52.809 | -63.984 |
| Net income (Group share) | -49.471 | -7.570 | -58.103 | -52.809 | -63.984 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Fonte: Cofisem - Ultimo aggiornamento: 29 Mar 2025 | |||||